[1]
“Pharmacoeconomic aspects related to the 13-valent pneumococcal conjugate vaccine: preliminary analysis of the data from the ASL of Viterbo”, FE, vol. 15, no. 4, pp. 155–159, Dec. 2014, doi: 10.7175/fe.v15i4.980.